Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAGUYAMA Study of factor VIII use during emicizumab prophylaxis in hemophilia A
jRCTs051210137Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jan 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of Factor VIII and emicizumab in hemophilia A, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Maximum coagulation velocity by modified clot waveform analysis after administration of factor VIII product. Started Jan 2022; status: completed.
02
Drugs
Factor VIIIemicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCTs051210137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051210137.